{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000167","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.845465+00:00","generated_at":"2026-05-28T03:09:54.468836+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Coherus provides preliminary Q4/FY2024 revenue and cash; UDENYCA allocated due to strong demand","bullets":["Preliminary unaudited net revenues for Q4 and FY2024 presented at J.P. Morgan Healthcare Conference.","Cash, cash equivalents and investments as of Dec 31, 2024 disclosed; final results may materially differ.","All three presentations of UDENYCA temporarily allocated due to strong demand in Q4 2024 and into Q1 2025.","Financial closing procedures not yet complete; independent auditor has not reviewed these preliminary results."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000167","json":"https://secwatch.observer/filing/0001558370-25-000167.json","markdown":"https://secwatch.observer/filing/0001558370-25-000167.md","text":"https://secwatch.observer/filing/0001558370-25-000167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025000167/0001558370-25-000167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025000167/chrs-20250113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:09:54.468836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}